Modulating drug impact by wrapping target proteins

Expert Opinion on Drug Discovery

Volumn 2, Issue 2, 2007, Pages 249-259

  Fernández, Ariel ^a,b   Scott, L Ridgway ^c  

^a Rice University   (United States)

^b THE UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cancer drug selectivity; Dehydron; Drug therapy; Imatinib derivative; Kinase targeting; Oncokinome; Side effect; Small molecule inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CHECKPOINT KINASE 1; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE; HYDROGEN; IMATINIB; INDINAVIR; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN KINASE; PROTEINASE; STAUROSPORINE; STEM CELL FACTOR;

CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; DRUG DESIGN; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG TARGETING; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; LIGAND BINDING; MOLECULAR INTERACTION; MOLECULAR THERAPY; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SEQUENCE HOMOLOGY;

EID: 34447530235     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.2.249     Document Type: Review

References (44)

1. LEVITSKI A, GAZIT A: Tyrosine kinase inhibition: an approach to drug development. Science (1995) 267:1782-1788.
2. DRUKER BJ: Molecularly targeted therapy: have the floodgates opened? Oncologist (2004) 9:357-360.
3. KNIGHT ZA, SHOKAT KM: Features of selective kinase inhibirors. Chem. Biol. (2005) 12:621-637.
4. HOPKINS AL, MASON JS, OVERINGTON JP: Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. (2006) 16:127-136.
5. FERNANDEZ A: Incomplete protein packing as a selectivity filter in drug design. Structure (2005) 13:1829-1836.
6. FERNANDEZ A, MADDIPATI S: A priori inference of cross reactivity for drug-targeted kinases. J. Med. Chem. (2006) 49:3092-3100.
7. FERNANDEZ A, SCOTT RL: Adherence of packing defects in soluble proteins. Phys. Rev. Lett. (2003) 91:018102.
8. FERNANDEZ A, SCHERAGA HA: Insufficiently dehydrated hydrogen bonds as determinants of protein interactions. Proc. Natl. Acad. Sci. USA (2003) 100:113-118.
9. FERNANDEZ A, PLAZONIC KR, SCOTT LR, SCHERAGA HA: Inhibitor design by wrapping packing defects in HIV-1 proteins. Proc. Natl. Acad. Sci. USA (2004) 101:11640-11645.
10. DEREMBLE C, LAVERY R: Macromolecular recognition. Curr. Opin. Struct. Biol. (2005) 15:171-175.
11. MA B, ELKAYAM T, WOLFSON H, NUSSINOV R: Protein - protein interactions: structurally conserved residues distinguish between binding sites and exposed protein surfaces. Proc. Natl. Acad. Sci. USA (2003) 100:5772-5777.
12. FABIAN MA, BIGGS WH, TREIBER DK et al.: A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotech. (2005) 23:329-336.
13. FLIRI AF, LOGING WT, THADEIO PF, VOLKMANN RA: Biological spectra analysis: linking biological activity profiles to molecular structure. Proc. Natl. Acad. Sci. USA (2005) 102:261-266.
14. MOUNT D: Bioinformatics. Cold Spring Harbor Laboratory Press, New York, USA (2001).
15. GUSFIELD D: Algorithms on Strings, Trees, and Sequences: Computer Science and Computational Biology. Cambridge University Press, Cambridge, UK (1997).
16. LEE B, RICHARDS FM: The interpretation of protein structures: estimation of static accessibility. J. Mol. Biol. (1971) 55:379-400.
17. COHEN MS, ZHANG C, SHOKAT KM, TAUNTON J: Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science (2005) 308:1318-1321.
18. BOGAN AA, THORN KS: Anatomy of hot spots in protein interfaces. J. Mol. Biol. (1998) 280:1-9.
19. NICHOLLS A, SHARP KA, HONIG B: Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins: Struct. Func. Genet. (1991) 11:281-296.
20. CHANDLER D: Interfaces and the driving force of hydrophobic assembly. Nature (2005) 437:640-647.
21. XU D, TSAI CJ, NUSSINOV R: Hydrogen bonds and salt bridges across protein-protein interfaces. Prot. Eng. (1997) 10:999-1012.
22. COHEN P: Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. (2002) 1:309-315.
23. FERNANDEZ A, BERRY RS: Molecular dimension explored in evolution to promote proteomic complexity. Proc. Natl. Acad. Sci. USA (2004) 101:13460-13465.
24. FERNANDEZ A: Conformation-dependent environments in folding proteins. J. Chem. Phys. (2001) 114:2489-2502.
25. FERNANDEZ A, BERRY RS: Extent of hydrogen-bond protection in folded proteins: a constraint on packing architectures. Biophys. J. (2002) 83:2475-2481.
26. FERNANDEZ A: Keeping dry and crossing membranes. Nat. Biotech. (2004) 22:1081-1084.
27. SCOTT LR, BOLAND M, ROGALE K, FERNANDEZ A: Continuum equations for dielectric response to macro-molecular assemblies at the nano scale. J. Physics A: Math. Gen. (2004) 37:9791-9803.
28. FERNANDEZ A, SCOTT LR: Dehydron: a structurally encoded signal for protein interaction. Biophys. J. (2003) 85:1914-1928.
29. DE SIMONEA, DODSON GG, VERMA CS, ZAGARI A, FRATERNALI F: Prion and water: tight and dynamical hydration sites have a key role in structural stability. Proc. Natl. Acad. Sci. USA (2005) 102:7535-7540.
30. FERNANDEZ A, SOSNICK TR, COLUBRI A: Dynamics of hydrogen-bond desolvation in folding proteins. J. Mol. Biol. (2002) 321:659-675.
31. FERNANDEZ A, BERRY RS: Proteins with H-bond packing defects are highly interactive with lipid bilayers: implications for amyloidogenesis. Proc. Natl. Acad. Sci. USA (2003) 100:2391-2396.
32. FERNANDEZ A, SCOTT LR: Under-wrapped soluble proteins as signals triggering membrane morphology:. J. Chem. Phys. (2003) 119:6911-6915.
33. FERNANDEZ A: Direct nanoscale dehydration of hydrogen bonds. J. Phys. D: App. Phys. (2005) 38:2928-2932.
34. SCHINDLER T, BORNMANN W, PELLICENA P et al.: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (2000) 289:1938-1942.
35. ATTOUB S, RIVAT C, RODRIGUES S et al.: The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res. (2002) 62:4879-4883.
36. MOL CD, DOUGAN DR, SCHNEIDER TR et al.: Structural basis for the autoinhibition and STI-571 Inhibition of c-Kit tyrosine kinase. J. Biol. Chem. (2004) 279:31655-31663.
37. MORPHY R, RANKOVIC Z: Designed multiple ligands, an emerging drug discovery paradigm. J. Med. Chem. (2005) 48:6523-6543.
38. ROTH BL, SHEFFLER DJ, KROEZE WK: Magic shotguns versus magic bullets: selectively selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. (2004) 3:353-359.
39. KERKELA R, GRAZETTE L, YACOBI R et al.: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. (2006) 12:908-916.
40. MANN D: Targeted cancer therapeutics: the heartbreak of success. Nat. Med. (2006) 12:881-882.
41. FISHMAN M, PORTER JA: Pharmaceuticals: a new grammar for drug discovery. Nature (2005) 437:491-493.
42. HARTSHORN M, MURRAY C: Fragment-based lead discovery using X-ray crystallography. J. Med. Chem. (2005) 48:403-413.
43. CARLSON HA, MCCAMMON JA: Accommodating protein flexibility in computational drug design. Mol. Pharmacol. (2000) 57:213-218.
44. CHRENCIK JE, ORAN'S J, MOORE L et al.: Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. Mol. Endocrinol. (2005) 19:1125-1134.